Despite being highly preventable, cervical cancer is the fourth most common cancer and
cause of cancer death in women globally. In low‐income countries, cervical cancer is often …

Background More than 10 years have elapsed since human papillomavirus (HPV)
vaccination was implemented. We did a systematic review and meta-analysis of the …

Background WHO is developing a global strategy towards eliminating cervical cancer as a
public health problem, which proposes an elimination threshold of four cases per 100 000 …

Background Cervical screening and human papillomavirus (HPV) vaccination have been
implemented in most high-income countries; however, coverage is low in low-income and …

The discovery of genotype 16 as the prototype oncogenic human papillomavirus (HPV)
initiated a quarter century of laboratory and epidemiological studies that demonstrated their …

Background Persistent infection with high‐risk human papillomaviruses (hrHPV) types is
causally linked with the development of cervical precancer and cancer. HPV types 16 and …

Background Funding for human papillomavirus (HPV) vaccination in Japan began in 2010
for girls aged 12–16 years, with three-dose coverage initially reaching more than 70%. On …

Introduction: Recently, the evidence on efficacy and safety of prophylactic HPV vaccines
derived from randomized trials was published in the Cochrane database of Systematic …

Background High-risk human papillomavirus causes cervical cancer. Vaccines have been
developed that significantly reduce the incidence of preinvasive and invasive disease. This …

Cervical cancer screening will rely, increasingly, on HPV testing as a primary screen. The
requirement for triage tests which can delineate clinically significant infection is thus …